{"id":"NCT03979313","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)","officialTitle":"A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-23","primaryCompletion":"2021-03-11","completion":"2023-03-21","firstPosted":"2019-06-07","resultsPosted":"2024-02-28","lastUpdate":"2024-02-28"},"enrollment":3012,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"DRUG","name":"MEDI8897","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MEDI8897","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy late preterm and term infants who are 35 weeks or greater gestational age and entering their first RSV season.","primaryOutcome":{"measure":"Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort)","timeFrame":"Through 150 Days Post Dose","effectByArm":[{"arm":"Placebo","deltaMin":25,"sd":null},{"arm":"Medi8897","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"0 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":198,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Chile","Colombia","Czechia","Estonia","Finland","France","Germany","Israel","Italy","Japan","Latvia","Lithuania","Mexico","New Zealand","Panama","Poland","Russia","South Africa","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["39656748","38902186","38219024","37468530","37018470","35235726","34774184"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5290C00004&amp;attachmentIdentifier=2d401e07-a37e-411e-8084-97fddbc8a78e&amp;fileName=D5290C00004_-_Protocol_Redacted_9aug2023_a.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5290C00004&amp;attachmentIdentifier=8b9437c7-c329-4235-8ace-9247ca221eed&amp;fileName=D5290C00004_-_Statistical_Analysis_Plan_Redacted_9aug2023_a.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5290C00004&amp;attachmentIdentifier=d2412c63-3b47-4c1e-a808-4f171d42b52a&amp;fileName=d5290c00004-study-synopsis-Redacted-9aug2023_a.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":83,"n":997},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Pyrexia","Dermatitis diaper","Rhinitis"]}}